Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAGE aptamer
- Development stage
- Preclinical
- Lead developer
- Kurume University
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Subcutaneous
01
Overview
RAGE aptamer is an experimental, preclinical phosphorothioate-modified single-stranded DNA oligonucleotide aptamer that acts as an antagonist of the receptor for advanced glycation end products (RAGE). Developed by researchers at Kurume University, it was selected via the SELEX method and binds to the V1-domain of RAGE with high affinity (Kd of approximately 5.68 nM). By blocking the interaction of advanced glycation end products (AGEs) and other ligands (such as HMGB1) with RAGE, the aptamer suppresses downstream oxidative stress, inflammatory pathways, and fibrotic signaling. It has demonstrated therapeutic potential in various preclinical animal models, including diabetic nephropathy, hypertensive renal injury, lupus nephritis, pulmonary arterial hypertension, sepsis, and malignant melanoma growth and metastasis.
- Other names
- DNA-aptamer directed against RAGERAGE-aptRAGE-aptamer
02
Targets
AGER (RAGE)
Beyond the preview
Go deeper on RAGE aptamer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAGE aptamer.